Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZRMT Regimen in PCNSL
NCT06445257Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in primary central nervous system lymphoma (PCNSL). Started Sep 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06445257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445257.